•Multi-omics reveals the associations among the fecal metabolome, intestinal bacteria, and serum indicators in patients with hepatocellular carcinoma
•Decoding prognosis in dengue-induced hepatitis: Model for end-stage liver disease vs albumin-bilirubin for predicting liver failure and survival
•Disproportionality Analysis of ALK Inhibitor-Induced Hemolytic Adverse Events: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
•Bilirubin metabolism in the liver orchestrates antiviral innate immunity in the body
•Relations between neurometabolism and clinical biomarkers in patients with metabolic disease